Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 15/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 12/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.68 |
| ▸ | PRKACA | P17612 | 3/20 | 0.64 |
| ▸ | PRKX | P51817 | 3/20 | 0.64 |
| ▸ | GSK3A | P49840 | 2/20 | 0.64 |
| ▸ | GSK3B | P49841 | 2/20 | 0.64 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.64 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.64 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | PRKCG | P05129 | 1/20 | 0.54 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | AKT1 | P31749 | 1/20 | 0.54 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20113592 | 0.84 | ROCK2 (0.78) | ROCK2ROCK1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL25718947 | 0.82 | ROCK2 (0.70) | ROCK2ROCK1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL20113556 | 0.81 | ROCK2 (1.00) | ROCK2ROCK1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL20113329 | 0.80 | ROCK2 (1.00) | ROCK2ROCK1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL20113746 | 0.80 | ROCK2 (0.80) | ROCK2ROCK1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1584297 | 0.79 | ROCK2 (1.00) | ROCK2ROCK1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL20113314 | 0.79 | ROCK2 (0.68) | ROCK2ROCK1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL25719565 | 0.79 | ROCK2 (0.68) | ROCK2ROCK1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL25719478 | 0.78 | ROCK2 (0.67) | ROCK2ROCK1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL25719042 | 0.77 | ROCK2 (0.79) | ROCK2ROCK1CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024039883-A2 | COMPOSITIONS AND METHODS TO TREAT MYELOPROLIFERATIVE DISORDERS AND MYELOPROLIFERATIVE NEOPLASMS | TRANSLATIONAL DRUG DEVELOPMENT LLC (US) | 2024-02-22 | — | — | WO | disclosed |
| EP-3532479-B1 | AMIDE COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEV LLC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230143583-A1 | AMIDE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS AND METHODS OF TREATMENT | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2023-05-11 | — | — | US | disclosed |
| US-20230143583-A1 | AMIDE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS AND METHODS OF TREATMENT | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2023-05-11 | — | — | US | disclosed |
| US-20210047335-A1 | AMIDE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS AND METHODS OF TREATMENT | TRANSLATIONAL DRUG DEVELOPMENT LLC | 2021-02-18 | — | — | US | disclosed |
| US-10738007-B2 | Amide compounds as kinase inhibitors, compositions and methods of treatment | Translation Drug Development, LLC (US) | 2020-08-11 | — | — | US | disclosed |
| WO-2020142745-A1 | METHODS OF TREATING GRAFT VERSUS HOST DISEASE AND NEOPLASTIC DISEASE WITH AMIDE COMPOUNDS | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2020-07-09 | — | — | WO | disclosed |
| US-20190248744-A1 | AMIDE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS AND METHODS OF TREATMENT | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2019-08-15 | — | — | US | disclosed |
| WO-2018081108-A1 | AMIDE COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143583-A1 | AMIDE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS AND METHODS OF TREATMENT | ROCK1, ROCK2, ARHGDIB | ROCK2 2/4885ROCK1 1/4885CYP3A4 4383/4885 |
| US-20190248744-A1 | AMIDE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS AND METHODS OF TREATMENT | ARHGDIB, ROCK2, ROCK1 | ROCK2 2/4885ROCK1 3/4885CYP3A4 4512/4885 |
| US-20210047335-A1 | AMIDE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS AND METHODS OF TREATMENT | ROCK1, ROCK2, ARHGDIB | ROCK2 2/4885ROCK1 1/4885CYP3A4 4383/4885 |
| US-10738007-B2 | Amide compounds as kinase inhibitors, compositions and methods of treatment | ARHGDIB, ROCK2, ROCK1 | ROCK2 2/4885ROCK1 3/4885CYP3A4 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.